TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions

Prior treatment with anti-PD-1 and/or BRAF-targeted therapies was associated with limited activity of tumor infiltrating lymphocytes (TIL) in metastatic melanoma. Recent insights into mechanisms of action for TIL and anti-PD-1 provide the foundation for understanding differences in outcomes in different trials or populations, and a roadmap for developing improved products.

Automated summary

Treatment with anti-PD-1 and/or BRAF-targeted therapies prior to metastatic melanoma was associated with limited activity of tumor infiltrating lymphocytes (TIL). Recent insights into the mechanisms of action for TIL and anti-PD-1 provide a foundation for understanding differences in outcomes in various trials or populations, and offer a roadmap for developing improved products.